Twist Bioscience Corporation $TWST Shares Purchased by New York State Common Retirement Fund

New York State Common Retirement Fund increased its stake in Twist Bioscience Corporation (NASDAQ:TWST) by 14.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 584,694 shares of the company’s stock after purchasing an additional 71,777 shares during the quarter. New York State Common Retirement Fund owned approximately 0.97% of Twist Bioscience worth $16,453,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of TWST. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Twist Bioscience by 15.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock worth $85,000 after buying an additional 302 shares during the last quarter. Geneos Wealth Management Inc. bought a new stake in Twist Bioscience in the 2nd quarter valued at $97,000. CWM LLC grew its stake in shares of Twist Bioscience by 61.4% in the 3rd quarter. CWM LLC now owns 4,331 shares of the company’s stock valued at $122,000 after purchasing an additional 1,648 shares during the period. Vanguard Personalized Indexing Management LLC grew its position in Twist Bioscience by 8.4% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 6,031 shares of the company’s stock valued at $222,000 after acquiring an additional 469 shares during the period. Finally, AXQ Capital LP bought a new stake in Twist Bioscience during the 2nd quarter worth approximately $226,000.

Analyst Ratings Changes

Several research analysts have recently issued reports on TWST shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, December 29th. Barclays raised their price objective on shares of Twist Bioscience from $37.00 to $39.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Evercore ISI restated an “outperform” rating and issued a $42.00 price target on shares of Twist Bioscience in a report on Monday, January 5th. Finally, Stephens began coverage on Twist Bioscience in a research note on Monday, November 3rd. They issued an “overweight” rating and a $41.00 target price on the stock. Eight analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $44.67.

Insider Buying and Selling at Twist Bioscience

In other news, CFO Adam Laponis sold 3,000 shares of Twist Bioscience stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $40.00, for a total value of $120,000.00. Following the completion of the sale, the chief financial officer owned 137,031 shares in the company, valued at $5,481,240. The trade was a 2.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Emily M. Leproust sold 1,605 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $34.56, for a total value of $55,468.80. Following the transaction, the chief executive officer directly owned 874,313 shares in the company, valued at $30,216,257.28. The trade was a 0.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 7,940 shares of company stock valued at $292,643. 3.08% of the stock is currently owned by corporate insiders.

Twist Bioscience Trading Down 1.2%

Shares of TWST stock opened at $41.07 on Monday. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $54.74. The company has a market capitalization of $2.52 billion, a PE ratio of -31.35 and a beta of 2.24. The firm has a 50 day moving average price of $35.25 and a two-hundred day moving average price of $31.56. The company has a quick ratio of 3.33, a current ratio of 3.64 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.05). The firm had revenue of $99.01 million during the quarter, compared to the consensus estimate of $97.40 million. Twist Bioscience had a negative net margin of 20.63% and a negative return on equity of 27.40%. As a group, analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.